Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Duitse aandelen  /  Bayer Jaardraadje 2024

Ontvang nu dagelijks onze kooptips!

word abonnee

Duitse aandelen« Terug naar discussie overzicht

Bayer Jaardraadje 2024

304 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste | Omlaag ↓
  4. forum rang 7 LL 10 januari 2024 10:53
    (CercleFinance.com) - Stifel downgrades its Bayer shares from 'buy' to 'hold', with a target price reduced from E68 to E42, preferring to 'stay on the sidelines', despite some upside potential for the stock, following a review of options for the German group.

    The broker considers that a separation from consumer healthcare 'can create value, but is no short-term solution for the stretched balance sheet', and believes that a separation from agrochemicals would destroy value.

    In conclusion, Stifel sees further downside potential for the consensus over the coming months, and estimates that EBITDA could decline by 11% in 2024, following a fall of around 20% last year.

    Copyright (c) 2024 CercleFinance.com. All rights reserved.
  9. forum rang 7 LL 11 januari 2024 14:13
    Bayer: begins heart failure study
    (CercleFinance.com) - Bayer announced on Thursday the start of a Phase II clinical trial to assess the efficacy of the AB-1002 gene therapy developed by its biotech subsidiary AskBio in the treatment of heart failure.

    The German group reports that it has enrolled the first patients in this trial, which is expected to enroll between 90 and 150 people in all, and will be conducted over 52 weeks in the US and Europe.

    Congestive heart failure occurs when the heart is unable to pump blood efficiently enough to meet the body's needs, notably to supply sufficient oxygen to the organs, and is characterised by a slowing of blood flow out of the heart.
  16. forum rang 7 LL 15 januari 2024 13:43
    BERLIN, Jan 15 (Reuters) - Germany's trade union IG BCE has pushed back against a possible split-up of drugmaker Bayer , which it says is envisaged by some shareholders, arguing such a move would endanger jobs in Germany.

    "For us, it's about keeping Bayer together," Michael Vassiliadis, leader of the IG BCE trade union, said in Berlin.

    A split-up would weaken individual company segments, making them more prone to takeovers, he said, adding that it was unclear whether the pharmaceuticals business or the company's headquarters would stay in Germany in such an event.

    Vassiliadis said CEO Bill Anderson's plans for a new management structure were currently being discussed. The trade union was not yet convinced of a reduction in middle management positions at Bayer, he said.

    (Reporting by Matthias Inverardi and Patricia Weiß, Writing by Nette Nöstlinger, Editing by Christina Fincher)
  17. forum rang 7 LL 18 januari 2024 13:10
    verklaring koersval:

    Jan 18 (Reuters) - German drugmaker Bayer AG is leaning against breaking up the conglomerate, rejecting pleas from investors amid the company's ongoing struggle to recover from its purchase of Monsanto, Bloomberg News reported on Thursday, citing people familiar with the matter.
  18. forum rang 6 effegenoeg 18 januari 2024 13:17
    quote:

    LL schreef op 18 januari 2024 13:10:

    verklaring koersval:

    Jan 18 (Reuters) - German drugmaker Bayer AG is leaning against breaking up the conglomerate, rejecting pleas from investors amid the company's ongoing struggle to recover from its purchase of Monsanto, Bloomberg News reported on Thursday, citing people familiar with the matter.
    Ik zie er ook niets in.
    Bij opknippen krijg je van elk toch weer een stukkie terug.
304 Posts
Pagina: «« 1 2 3 4 5 6 ... 16 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 912,23 0,00%
EUR/USD 1,0850 -0,09%
FTSE 100 8.254,18 0,00%
Germany40^ 18.629,90 -0,26%
Gold spot 2.352,78 -0,36%
NY-Nasdaq Composite 17.019,88 +0,59%

Stijgers

AB InBev
0,00%
Ackerm...
0,00%
Aedifica
0,00%
Ageas
0,00%
Aperam
0,00%

Dalers

AB InBev
0,00%
Ackerm...
0,00%
Aedifica
0,00%
Ageas
0,00%
Aperam
0,00%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!